Clinical Trial Update: Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the immunogenicity and reactogenicity of GSK DTPa-HBV-IPV and Hib vaccines when coadministered to healthy infants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Hepatitis B
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• DTPa-HBV-IPV vaccine (Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, and Inactivated Poliovirus Vaccine)
• Haemophilus influenzae type b conjugate vaccine (Haemophilus influenzae type b conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diphtheria, Poliomyelitis | Phase 3 | Status: COMPLETED